

UHSM - PERFORMANCE IN INITIATING Quarter 4 2015/2016

Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Date Study Initiated	Date Site Initiated	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
15/NW/0100	166703	NHS Permission	Detection of atrial fibrillation in community locations using novel technology's as a method of stroke prevention in the over 65's asymptomatic population should it become standard practice	02/04/2015	13/04/2015	Yes	14/04/2015	11	1	12	Yes																				Please Select...
15/LO/0018	167680	NHS Permission	A Randomized double blind placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm	07/04/2015	10/04/2015	Yes	10/06/2015	3	61	64	Yes																				Please Select...
15/EE/0003	167949	NHS Permission	A randomized, double-blind, placebo-controlled Phase 3 study of ISIS 304801 administered subcutaneously to patients with hypertriglyceridemia	09/04/2015	13/04/2015	Yes	09/10/2015	4	179	183	No												Y						Patients screened but no eligible patients identified.	Neither	
14/EM/1141	167949	NHS Permission	A randomized double blind placebo controlled phase 3 study of ISIS 304801 administered subcutaneously to patients with familial chylomicronemia syndrome	14/04/2015	14/04/2015	Yes	12/08/2015	0	120	120	No												Y						Patients screened but no eligible patients identified.	Neither	
15/NW/0255	163780	NHS Permission	A phase 3, multi-center, randomised, open-label study of Carbazepine (Meropenem/RPX7009) versus best available therapy in subjects with selected serious infections due to Carbapenem-resistant Enterobacteriaceae	20/05/2015	29/05/2015	Yes	08/07/2015	9	40	49	Yes																				Please Select...
14/NW/1337	163452	NHS Permission	A Multicentre, Randomised, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-Acting B2-Agonist (BORA)	16/06/2015	17/06/2015	Yes	01/07/2015	1	14	15	Yes																				Please Select...
14/LO/0324	146711	NHS Permission	A multi-centre, randomised, double-blind, placebo-controlled study to Evaluate the Safety and Efficacy of Pulmaquin? in the Management of Chronic Lung Infections with Pseudomonas Aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension and Pharmacokinetic Substudy	25/06/2015	30/06/2015	Yes	14/07/2015	5	14	19	Yes																				Please Select...
12/WM/0335	97743	NHS Permission	A pilot study for developing and evaluating a care pathway for cognitive problems after stroke (OCS-care)	02/06/2015	18/06/2015	Yes	13/07/2015	16	25	41	Yes																				Please Select...
12/YH/0539	113983	NHS Permission	an open label multi centre preoperative window of opportunity study of afatinib in stage Ia to Ib non-small cell lung cancer	11/05/2015	01/06/2015	No		21			No												Y				Y	Main source of delay is F patients screened but no eligible patients identified. Low recruitment target 1-2 patients per year as this is the main source of the delay the source is neither. The delay also relates to J Other; there was a lengthy period of technical problems at the Christie with the PET scans so we couldn't start screening straight away.	Neither		
15/NW/0163	156862	NHS Permission	PATHWAY: Improving the effectiveness of Psychological Interventions for Depression and Anxiety in the Cardiac Rehabilitation Pathway. A single-blind, pilot, randomised, controlled trial with four-month and twelve-month follow-up comparing MCT plus usual CR (intervention) with usual CR (control).	09/06/2015	11/06/2015	Yes	23/07/2015	2	42	44	Yes																				Please Select...
15/WA/0132	173287	NHS Permission	EPIC AAA Study: Exercise Capacity, Physical Inactivity and Cardiovascular Risk in AAA Patients	08/04/2015	29/04/2015	Yes	14/05/2015	21	15	36	Yes																				Please Select...
14/EM/1280	163096	NHS Permission	A randomised controlled trial to investigate the effectiveness of ThOracic epidural and Paravertebral blockade in thoracotomy pain - TOPIC Feasibility Study	04/08/2015	17/08/2015	Yes	14/09/2015	13	28	41	Yes																				Please Select...
15/NW/0485	150625	NHS Permission	The Goal Directed Perfusion Trial	27/08/2015	01/09/2015	Yes	15/09/2015	5	14	19	Yes																				Please Select...
15/NW/0022	160532	NHS Permission	A multicentre randomised clinical trial to investigate whether Bone Anchored Maxillary Protraction (BAMP) reduces the need for orthognathic (facial) surgery	23/07/2015	23/09/2015	No		62			No										Y			Y						Main source of delay(VRA to FPR) is F No Patients Seen - due to Strict patient eligibility criteria and low recruitment target as this is the main source of delay the source is neither. VRA to NHS is over 30 days due to the SSI being submitted before the research admin team were aware of the study to collate documents and set up the study.	Neither
14/NE/1176	161888	NHS Permission	Multi-centre randomised controlled trial with economic evaluation and nested qualitative study comparing early structured physiotherapy versus manipulation under anaesthesia versus arthroscopic capsular release for patients referred to secondary care with a frozen shoulder (Adhesive Capsulitis)	17/08/2015	01/09/2015	Yes	22/09/2015	15	21	36	Yes																				Please Select...
15/NW/0371	172337	NHS Permission	ReaDySpeech for people with dysarthria after stroke: a feasibility study	16/06/2015	20/07/2015	Yes	15/09/2015	34	57	91	No													Y			Y	Main source of delay was E NHS Provider staff availability - recruitment could not begin within 70 days due to staff being on annual leave. VRA to NHS was over 30 days due to A local review not completed in time (SSI was submitted too soon.)	NHS Provider		
14/LO/1800	146057	NHS Permission	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the addition of Co-trimoxazole (EME-TIPAC)	07/09/2015	22/09/2015	Yes	03/11/2015	15	42	57	Yes																				Please Select...
14/NW/1497	166166	NHS Permission	The Role of GABA(B) Receptor Mechanisms in Cough: Double-Blind Randomised Controlled Trial of Lesgaberan in Chronic Cough Patients with Positive and Negative Symptom Association Probabilities	10/07/2015	10/07/2015	Yes	23/07/2015	0	13	13	Yes																				Please Select...
15/EM/0294	180267	NHS Permission	A Phase 3 Randomised, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot Ulcer	22/09/2015	29/09/2015	Yes	26/10/2015	7	27	34	Yes																				Please Select...
14/YH/1199	153953	NHS Permission	GALACTIC: GA101 (obinituzumab) monoclonal Antibody as Consolidation Therapy in CLL	16/09/2015	02/10/2015	Yes	19/10/2015	16	17	33	Yes																				Please Select...
14/YH/1162	154011	NHS Permission	A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered higher risk of complication from surgical resection	25/09/2015	09/10/2015	Yes	19/02/2016	14	133	147	No													Y						Patients screened but no eligible patients identified.	Neither
15/YH/0178	174447	NHS Permission	A Phase 3, Randomized, Double-Blinded, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in combination with Ivacaftor in subjects aged 12 years and older with Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a second CFTR Allele with a gating defect that is clinically demonstrated to be Ivacaftor responsive	05/10/2015	12/10/2015	Yes	26/10/2015	7	14	21	Yes																				Please Select...
14/SC/0171	120104	NHS Permission	A phase III, double-blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.	15/10/2015	22/10/2015	Yes	14/12/2015	7	53	60	Yes																				Please Select...
14/LO/2195	165351	NHS Permission	Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer	20/10/2015	26/10/2015	Yes	30/11/2015	6	35	41	Yes																				Please Select...
15/LO/1289	181953	NHS Permission	An international, multicentre, randomised, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures	29/10/2015	02/11/2015	No		4			No													Y					Patients screened but no eligible patients identified. Strict patient eligibility criteria, we are using the 30% of patients seen who are resistant to Clopidogrel This makes the trial very difficult to recruit to.	Neither	
15/NW/0032	151852	NHS Permission	Imaging cerebral neuroinflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guiding treatment (IN-CVD)	01/10/2015	05/11/2015	Yes	10/11/2015	35	5	40	Yes																				Please Select...
15/EE/0130	170557	NHS Permission	A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment	27/10/2015	09/11/2015	No		13			No												Y							Patients screened but no eligible patients identified	Neither
14/YH/0128	150031	NHS Permission	Sacral nerve stimulation versus the FENIX magnetic sphincter augmentation for adult faecal incontinence: a Randomised Investigation (SaFAR)	09/11/2015	10/11/2015	Yes	10/02/2016	1	92	93	No													Y					Eligible patients seen chose not to participate in the study, other options have been available to the patients and they do not want such an evasive procedure	Neither	
15/NW/0724	173790	NHS Permission	Evaluation of the fast fill technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter (PI - Mr Nicholas Heywood)	28/10/2015	11/11/2015	Yes	11/11/2015	14	0	14	Yes																				Please Select...
15/LO/0699	173824	NHS Permission	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function	13/11/2015	19/11/2015	Yes	18/12/2015	6	29	35	Yes																				Please Select...
11/SS/0100	84669	NHS Permission	Fluoxetine Or Control Under Supervision	22/10/2015	25/11/2015	Yes	19/01/2016	34	55	89	No										Y			Y					The main reason for NHS to FPR being over 70 days is No eligible patients seen - strict patient eligibility criteria this is why the reason is neither. The VRA to NHS was over 30 days due to the fact the local review not completed in time.	Neither	

